159323-96-3

Upstream product

• 64-17-5 ethanol 
• 7195-78-0 5-chloro-2-hydroxy-3-nitrobenzoic acid 
• 321-14-2 5-chloro-2-hydroxybenzoic acid 
• 15196-83-5 5-chlorosalicylic acid ethyl ester 
• 75-03-6 ethyl iodide 

Downstream Products

• 89692-61-5 5-chloro-2-hydroxy-3-nitro-benzoic acid amide 
• 149140-78-3 ethyl 3-aminio-5-chloro-2-hydroxybenzoate 
• 149140-66-9 ethyl 2-hydroxy-3-(pyrrol-1-yl)benzoate 
• 149140-56-7 ethyl 5-chloro-2-hydroxy-3-(pyrrol-1-yl)benzoate 
• 149140-62-5 ethyl 5-chloro-2-hydroxy-3-(2-hydroxymethylpyrrol-1-yl)benzoate 
• 149140-59-0 ethyl 2-acetoxy-5-chloro-3-(pyrrol-1-yl)benzoate 
• 149140-61-4 ethyl 5-chloro-3-(2-formylpyrrol-1-yl)-2-hydroxybenzoate 
• 149140-60-3 ethyl 2-acetoxy-5-chloro-3-(2-formylpyrrol-1-yl)benzoate 

Relevant academic research and scientific papers

Development of a Phase-Transfer-Catalyzed, [2,3]-Wittig Rearrangement

An investigation into the use of phase-transfer catalysis for the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds is described. Initial studies focused on identifying viable substrate classes that would undergo selective [2,3]-rearrangement under phase-transfer catalysis. Under certain conditions, the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds takes place in the presence of a phase-transfer agent, providing a rare example of a phase-transfer-catalyzed unimolecular reaction. In the course of this investigation, it was found that catalysis is dependent on several variables including base concentration, catalyst structure, and substrate lipophilicity. Preliminary testing of chiral, nonracemic phase-transfer catalysts has shown promising levels of enantioselectivity for future development.

BENZOXAZOLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT

A compound represented by the following general formula (1) : wherein R1 represents a halogen atom, R2 represents hydrogen atom or a lower alkyl group, and R3 represents hydrogen atom, a lower alkyl group, a lower alkoxyl group, a hydroxy lower alkyl group, a halogen atom, or a substituted or unsubstituted amino group, wherein a substituent on the amino group is selected from the group consisting of a lower alkyl group, a lower alkenyl group, a lower alkylcarbonyl group, and an amino protective group, or a salt thereof. The compound of the present invention or a salt thereof is useful as an active ingredient of medicaments for preventive and/or therapeutic treatment of conditions of irritable bowel syndrome and digestive tract functional disorder, or condition of diarrhea.

Synthesis and Enzymatic Evaluation of Conformationally Defined Carnitine Analogs

Carnitine (1, 3-hydroxy-4-trimethylammoniobutyrate) is essential as a donor and acceptor of acyl groups in cellular metabolism.The major solution conformation of carnitine about C3-C4 contains the gauche reletionship between the trimethylammonium and hydr